Drug-induced hemolytic anemia: Pharmacological aspects.

Détails

ID Serval
serval:BIB_5FDB97D09073
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Drug-induced hemolytic anemia: Pharmacological aspects.
Périodique
Transfusion clinique et biologique
Auteur(s)
Renard D., Rosselet A.
ISSN
1953-8022 (Electronic)
ISSN-L
1246-7820
Statut éditorial
Publié
Date de publication
09/2017
Peer-reviewed
Oui
Volume
24
Numéro
3
Pages
110-114
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Drug-induced hemolytic anemia is a very rare but potentially lethal adverse drug reaction, which can take the form of oxidative damage to vulnerable erythrocytes (as in glucose-6-phosphate dehydrogenase deficiency), drug-induced thrombotic microangiopathy, or immune-mediated hemolytic anemia. For each form, distinctive drugs are documented as potential triggers. When a formal diagnosis of hemolytic anemia is made following drug administration, a structured approach is recommended to assess the plausibility of an adverse drug reaction based on chronological sequence, epidemiological data, objective evidence (when available), and ruling out of non-drug causes. For suspicions of immune-mediated hemolytic anemia, investigations by a laboratory with specific expertise are crucial given the complexity of the field. If there is good reason to believe hemolytic anemia is drug-induced, immediate drug discontinuation is necessary and corticosteroid administration can be considered. The clinical pharmacology specialist can support evaluation of drug imputability and report the case to the pharmacovigilance system, an important last step in managing such events.
Mots-clé
Adrenal Cortex Hormones/therapeutic use, Anemia, Hemolytic/chemically induced, Anemia, Hemolytic/epidemiology, Anemia, Hemolytic/etiology, Anemia, Hemolytic/physiopathology, Anemia, Hemolytic, Autoimmune/blood, Anemia, Hemolytic, Autoimmune/complications, Anti-Bacterial Agents/adverse effects, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Causality, Diagnosis, Differential, Disease Management, Disease Susceptibility, Glucosephosphate Dehydrogenase Deficiency/blood, Glucosephosphate Dehydrogenase Deficiency/complications, Humans, Osmotic Fragility, Oxidants/adverse effects, Oxidative Stress, Pharmacovigilance, Thrombotic Microangiopathies/blood, Thrombotic Microangiopathies/chemically induced, Anemia hemolytic, Anémie hémolytique, Drug hypersensitivity, Drug-related side effects and adverse reactions, Effet indésirable médicamenteux, Réaction d’hypersensibilité
Pubmed
Web of science
Création de la notice
06/07/2017 17:54
Dernière modification de la notice
20/08/2019 15:17
Données d'usage